VS-105 is under clinical development by Vidasym and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect VS-105’s likelihood of approval (LoA) and phase transition for Chronic Kidney Disease (Chronic Renal Failure) took place on 13 Aug 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 13 Aug 2021 increased VS-105’s LoA and PTSR for Secondary Hyperparathyroidism.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their VS-105 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

VS-105 overview

VS-105 is under development for the treatment of  osteoporosis, secondary hyperparathyroidism in chronic kidney disease, inflammatory bowel disease, psoriasis. It is administered through oral route. VS-105 acts by targeting vitamin D receptor.

It was under development for diabetic nephropathy, non-alcoholic steatohepatitis (NASH), non alcoholic fatty liver disease (NAFLD).

Vidasym overview

Vidasym operates in pharmaceutical and healthcare industry. It is headquartered in United States.

Quick View VS-105 LOA Data

Report Segments
  • Innovator
Drug Name
  • VS-105
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Hormonal Disorders
  • Immunology
  • Metabolic Disorders
  • Musculoskeletal Disorders
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.